Take 100 Megabytes a Day and Call Me in the Morning

Episode Summary

Executive Summary: The episode examines the rapid expansion of digital health, especially prescription digital therapeutics, AI-enabled diagnostics, and digital endpoints in drug development. Murray Aitken of IQVIA says the sector is maturing after funding turbulence, with clearer regulatory and reimbursement pathways helping adoption. He argues that unmet clinical need, better sensors, and AI are driving growth, while evidence and physician/payer acceptance remain key to broader use.

Main Topics: Expansion of digital health beyond consumer apps (Priority: 5/5): Digital health now spans tools used across the care continuum by patients, clinicians, providers, and drug developers, not just consumer wellness products. AI in diagnostics and personalization (Priority: 5/5): AI and machine learning are increasingly embedded in digital diagnostics and monitoring tools, supporting disease detection, progression prediction, and tailored recommendations. Funding pullback and sector maturation (Priority: 4/5): After the 2020-2021 funding surge, digital health companies faced a tougher capital environment, leading to exits and restructuring, but also a more realistic market. Growth and regulation of digital therapeutics (Priority: 5/5): Prescription digital therapeutics have grown sharply, but regulatory pathways and evidence requirements still vary across regions and risk levels. Reimbursement and physician adoption (Priority: 4/5): Clearer billing codes, payer coverage, and practical workflows are improving acceptance among clinicians and payers, though comfort and evidence remain necessary. Digital health in drug development (Priority: 4/5): Sensors, remote monitoring, and digital endpoints are increasingly used in clinical trials to reduce burden, improve data capture, and potentially lower costs.

Key Arguments: Digital health growth is being driven by unmet medical needs, expanding sensor capabilities, and sustained startup investment. AI is not separate from digital health; it is becoming embedded in diagnostics, prediction, and personalized self-care recommendations. The sector’s financial challenges largely reflect the post-2020/2021 funding correction rather than a lack of utility or demand. Regulatory and reimbursement clarity has improved in the U.S., Germany, the UK, and other markets, helping the field mature. Digital therapeutics are defined by delivering a medical intervention via software, and their adoption depends on clinical evidence and safety. Physicians and payers will adopt digital therapeutics more widely when they see outcomes, receive payment for time spent, and gain confidence from peers. Digital tools can make clinical trials less burdensome, capture continuous real-world data, and support FDA-approved digital endpoints. The biggest long-term impact is likely improved patient care through better data, lower burden, and potentially lower costs than conventional approaches.

Data Points: Commercially available prescription digital therapeutics: 140 - Market access through national regulatory and reimbursement pathways Growth in prescription digital therapeutics since 2021: Five-fold increase - As cited from the IQVIA Digital Health Trends 2024 report Digital care programs since 2021: Doubled - Broader offerings that include digital therapeutics plus other care elements AI-enabled mobile digital diagnostics: 103 - Commercially available for health assessment FDA-approved devices incorporating AI: About 75 - Examples include autism spectrum disorders, sleep apnea, atrial fibrillation, skin cancers, and epilepsy Pain reduction in pediatric virtual reality use: 60% reduction - Australia-approved device used to minimize pain during needle procedures Anxiety reduction in pediatric virtual reality use: 40% reduction - Same virtual reality device for children during needle procedures Report history: 5th report since 2013 - IQVIA Institute’s digital health report series

Pivotal Quotes: "the scope of what gets included under digital health has expanded very rapidly" — Murray Aitken: Describing how broad the digital health category has become in the new IQVIA report "we're definitely seeing AI being incorporated into digital health tools in one way or another" — Murray Aitken: On AI’s growing role across digital diagnostics and therapeutic applications "the need and the opportunity for digital health remains as actually larger than ever" — Murray Aitken: Explaining why the sector outlook stays positive despite funding disruption

Implications: Digital health is moving from experimentation to integration. Companies that prove clinical value, secure reimbursement, and fit clinician workflows are best positioned, while AI and digital endpoints may reshape care delivery and drug development alike.